Brokers Offer Predictions for GT Biopharma FY2029 Earnings

GT Biopharma, Inc. (NASDAQ:GTBP) – Research analysts at Roth Capital issued their FY2029 earnings estimates for shares of GT Biopharma in a research report issued to clients and investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff expects that the company will earn $0.33 per share for the year. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for GT Biopharma’s current full-year earnings is ($6.79) per share.

Separately, Roth Mkm initiated coverage on shares of GT Biopharma in a report on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective for the company.

GT Biopharma Trading Up 3.5 %

NASDAQ GTBP opened at $2.38 on Thursday. The company has a fifty day simple moving average of $2.44 and a 200 day simple moving average of $2.47. The company has a market cap of $5.32 million, a P/E ratio of -0.34 and a beta of 0.59. GT Biopharma has a 1 year low of $1.72 and a 1 year high of $10.66.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.